Product
PPSV23
Aliases
Pneumovax 23, PNEUMOVAX™23
11 clinical trials
9 indications
Indication
Pneumococcal InfectionIndication
pneumococcal diseaseIndication
PneumoniaIndication
BacteriaIndication
Healthy Control ParticipantsIndication
PneumococcalIndication
HealthyIndication
Chronic Lymphocytic LeukemiaIndication
Vaccine ResponseClinical trial
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 18 to 64 Years of Age With Increased Risk for Pneumococcal DiseaseStatus: Completed, Estimated PCD: 2024-02-16
Clinical trial
A Phase 3 Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults 18 to 49 Years of AgeStatus: Completed, Estimated PCD: 2023-05-25
Clinical trial
A Phase 1/2, Randomized, Single Ascending Dose Study in Adults (Stage 1) and Randomized, Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, a Pneumococcal VaccineStatus: Completed, Estimated PCD: 2020-09-28
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults Living With HIVStatus: Completed, Estimated PCD: 2023-07-13
Clinical trial
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal DiseaseStatus: Recruiting, Estimated PCD: 2025-02-12
Clinical trial
A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or OlderStatus: Completed, Estimated PCD: 2023-05-16
Clinical trial
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Japanese Adults 65 Years of Age or OlderStatus: Completed, Estimated PCD: 2023-05-24
Clinical trial
A Randomized, Open-Label Study on the Effect of Nipocalimab on Vaccine Responses in Healthy ParticipantsStatus: Completed, Estimated PCD: 2023-10-04
Clinical trial
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or OlderStatus: Active (not recruiting), Estimated PCD: 2023-10-30
Clinical trial
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, THIRD-PARTY-UNBLINDED TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 60 YEARS OF AGE AND OLDER IN JAPAN, KOREA, AND TAIWANStatus: Completed, Estimated PCD: 2022-05-13
Clinical trial
Long Term Effect on Immune Response After Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukemia and Evaluation of the Effect of RevaccinationStatus: Completed, Estimated PCD: 2021-06-30